-
Signature
-
/s/ Dov Bergwerk as attorney-in-fact for Eliyahu Sharon Kalif
-
Issuer symbol
-
TEVA
-
Transactions as of
-
12 Jun 2025
-
Net transactions value
-
-$952,464
-
Form type
-
4
-
Filing time
-
16 Jun 2025, 16:03:30 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Kalif Eliyahu Sharon |
EVP, Chief Financial Officer |
C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, ISRAEL |
/s/ Dov Bergwerk as attorney-in-fact for Eliyahu Sharon Kalif |
16 Jun 2025 |
0001798443 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
TEVA |
Ordinary Shares |
Sale |
$952,464 |
-55,775 |
-12% |
$17.08 |
403,288 |
12 Jun 2025 |
Direct |
F1, F2, F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: